Mehmet Suat YALÇIN, Serkan YALAKİ, Şehmus ÖLMEZ, Adnan TAŞ

Monocyte/High-Density Lipoprotein Ratio Is an Indicator of Activity in Patients with Ulcerative Colitis

Background: In patients with ulcerative colitis, endoscopic and clinical indices are used to assess the disease activity. In addition, stud- ies have been carried out for easier and cheaper markers in recent years. For this purpose, we evaluated the monocyte/high-density lipoprotein ratio of the disease activity. Methods: According to clinical activity and partial Mayo scores, a total of 114 patients, 53 in the active ulcerative colitis group and 61 in the ulcerative colitis remission group were included in the study. Monocyte/high-density lipoprotein ratio, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, C-reactive protein, and erythrocyte sedimentation rate measurements of these 2 groups were recorded. Ulcerative colitis remission group and active ulcerative colitis group were compared in terms of activity. Results: The monocyte/high-density lipoprotein ratio value in the active ulcerative colitis group was significantly higher than that of the ulcerative colitis remission group (10.68 ± 3.39, 6.68 ± 1.39, P < .001, respectively). The monocyte/high-density lipoprotein ratio value for active ulcerative colitis at a cut-off value of 7.4 had 83% sensitivity and 81% specificity. In the active ulcerative colitis group, neutrophil/lymphocyte ratio, C-reactive protein, and erythrocyte sedimentation rate values were significantly higher than the ulcerative colitis remission group (P < .001, P < .001, P < .001, respectively). Conclusion: Monocyte/high-density lipoprotein ratio is an inexpensive and effective marker that can be used to determine the activity of ulcerative colitis

Tam Metin

___

1. El-Kheshen G, Moeini M, Saadat M. Susceptibility to ulcerative colitis and genetic polymorphisms of A251G SOD1 and C-262T CAT. J Med Biochem. 2016;35(3):333-336. [CrossRef]

2. DeRoche TC, Xiao SY, Liu X. Histological evaluation in ulcerative colitis. Gastroenterol Rep. 2014;2(3):178-192. [CrossRef]

3. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769- 2778. [CrossRef]

4. Osterman MT, Lichtenstein GR. Ulcerative colitis. In: Feldman M, Friedman LS, Brandt JL, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th ed. Philadelphia: Saunders; 2016:2023-2061.

5. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041-1048. [CrossRef]

6. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817- 1826.e2. [CrossRef]

7. Sayar S, Kurbuz K, Kahraman R, et al. A practical marker to deter- mining acute severe ulcerative colitis: CRP/albumin ratio. North Clin Istanb. 2020;7(1):49-55. [CrossRef]

8. Kundi H, Kiziltunc E, Cetin M, et al. Association of monocyte/ HDL-C ratio with SYNTAX scores in patients with stable coronary artery disease. Herz. 2016;41(6):523-529. [CrossRef]

9. Ganjali S, Gotto AM Jr, Ruscica M, et al. Monocyte-to-HDL-cho- lesterol ratio as a prognostic marker in cardiovascular diseases. J Cell Physiol. 2018;233(12):9237-9246. [CrossRef]

10. Canpolat U, Çetin EH, Cetin S, et al. Association of monocyte-to- HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clin Appl Thromb Hemost. 2016;22(5):476- 482. [CrossRef]

11. Ossoli A, Remaley AT, Vaisman B, Calabresi L, Gomaraschi M. Plasma-derived and synthetic high-density lipoprotein inhibit tissue factor in endothelial cells and monocytes. Biochem J. 2016;473(2):211- 219. [CrossRef]

12. Vahit D, Akboga MK, Samet Y, Hüseyin E. Assessment of mono- cyte to high density lipoprotein cholesterol ratio and lymphocyte-to- monocyte ratio in patients with metabolic syndrome. Biomark Med. 2017;11(7):535-540. [CrossRef]

13. Seo WS, Oh HS. The circadian rhythms of blood pressure and heart rate in the hypertensive subjects: dippers and non-dippers. Yonsei Med J. 2002;43(3):320-328. [CrossRef]

14. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-amino- salicylic acid therapy for mildly to moderately active ulcerative coli- tis: a randomized study. N Engl J Med. 1987;317(26):1625-1629. [CrossRef]

15. Rutka M, Milassin Á, Szepes Z, et al. Is mucosal healing more common than clinical remission in ulcerative colitis? Is it the truth or only a myth coming from the studies? Scand J Gastroenterol. 2015;50(8):985-990. [CrossRef]

16. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E. Monocytes in coronary artery disease and atherosclerosis: where are we now? J Am Coll Cardiol. 2013;62(17):1541-1551. [CrossRef]

17. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell prolifera- tion. Science. 2010;328(5986):1689-1693. [CrossRef]

18. Kuvin JT, Patel AR, Sidhu M, et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Car- diol. 2003;92(3):275-279. [CrossRef]

19. Kaplan IG, Kaplan M, Abacioglu OO, Yavuz F, Saler T. Monocyte/ HDL ratio predicts hypertensive complications. Bratisl Lek Listy. 2020;121(2):133-136. [CrossRef]

20. Cakmak BD, Dundar B, Gencer FK, Aydin BB, Yildiz DE. TWEAK and monocyte to HDL ratio as a predictor of metabolic syndrome in patients with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35(1):66-71. [CrossRef]

21. Kanbay M, Solak Y, Unal HU, et al. Monocyte count/HDL choles- terol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014;46(8):1619-1625. [CrossRef